Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01553149 · OUTCOME

Overall Survival [OS]

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma · Source last updated 2025-01-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent Probability
Interval / dispersion
95% Confidence Interval
Time frame
Up to 3 years after study enrollment

What was measured

Estimated 3-year overall survival is calculated as the time from study enrollment to death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients alive at last contact are censored at that time.

Analysis population: Only eligible patients are considered in the analysis of this outcome measure

Groups in this outcome

Arm I (Low-dose Lenalidomide)

Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Lenalidomide: Given PO Pharmacological Study: Correlative studies

Arm II (High-dose Lenalidomide)

Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Lenalidomide: Given PO Pharmacological Study: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Low-dose Lenalidomide)37
Arm II (High-dose Lenalidomide)37

Reported measurements

Source class 1
Values in Percent Probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I (Low-dose Lenalidomide)94.59Not reported80.0798.62Not reported
Arm II (High-dose Lenalidomide)91.74Not reported76.5297.26Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        80.07
        upper Limit
        98.62
        value
        94.59
      2. group Id
        OG001
        lower Limit
        76.52
        upper Limit
        97.26
        value
        91.74
denoms
  1. counts
    1. group Id
      OG000
      value
      37
    2. group Id
      OG001
      value
      37
    units
    Participants
description
Estimated 3-year overall survival is calculated as the time from study enrollment to death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients alive at last contact are censored at that time.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Lenalidomide: Given PO Pharmacological Study: Correlative studies
    id
    OG000
    title
    Arm I (Low-dose Lenalidomide)
  2. description
    Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Lenalidomide: Given PO Pharmacological Study: Correlative studies
    id
    OG001
    title
    Arm II (High-dose Lenalidomide)
param Type
NUMBER
population Description
Only eligible patients are considered in the analysis of this outcome measure
reporting Status
POSTED
time Frame
Up to 3 years after study enrollment
title
Overall Survival [OS]
type
SECONDARY
unit Of Measure
Percent Probability

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice